Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinases

eLife

Volumn 5, Issue DECEMBER2016, 2016, Pages

  Clarke, Paul A ^a   Ortiz Ruiz, Maria Jesus ^a   Tepoele, Robert ^a   Adeniji Popoola, Olajumoke ^a   Box, Gary ^a   Court, Will ^a   Czasch, Stephanie ^b   El Bawab, Samer ^b   Esdar, Christina ^b   Ewan, Ken ^c   Gowan, Sharon ^a   Brandon, Alexis De Haven ^a   Hewitt, Phillip ^b   Hobbs, Stephen M ^a   Kaufmann, Wolfgang ^b   Mallinger, Aurélie ^a   Raynaud, Florence ^a   Roe, Toby ^a   Rohdich, Felix ^b   Schiemann, Kai ^b   Simon, Stephanie ^b   Schneider, Richard ^b   Valenti, Melanie ^a   Weigt, Stefan ^b   Blagg, Julian ^a   Blaukat, Andree ^b   Dale, Trevor C ^c   Eccles, Suzanne A ^a   Hecht, Stefan ^b   Urbahns, Klaus ^b   Workman, Paul ^a   Wienke, Dirk ^b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MERCK KGAA   (Germany)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE 19; CYCLIN DEPENDENT KINASE 8; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IRINOTECAN; OXALIPLATIN; PEPTIDES AND PROTEINS; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CDK19 PROTEIN, HUMAN; CDK8 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; MEDIATOR COMPLEX; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; IMMUNE RESPONSE; INFLAMMATION; MORPHOGENESIS; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HUMAN; HYPERPLASIA; MOUSE; NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE 8; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; HYPERPLASIA; MEDIATOR COMPLEX; MICE; NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 85009349933     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.20722.001     Document Type: Article

References (54)

1. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM, Firestein R. 2012. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Research 72: 2129–2139. doi: 10.1158/0008-5472.CAN-11-3886, PMID: 22345154
2. Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, Sapkota G, Pan D, Massagué J. 2009. Nuclear CDKs drive smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139:757–769. doi: 10.1016/j.cell.2009.09.035, PMID: 19914168
3. Allen BL, Taatjes DJ. 2015. The mediator complex: a central integrator of transcription. Nature Reviews Molecular Cell Biology 16:155–166. doi: 10.1038/nrm3951, PMID: 25693131
4. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dölken L, Strobl B, Müller M, Taatjes DJ, Kovarik P. 2013. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38:250–262. doi: 10.1016/j.immuni.2012.10.017, PMID: 23352233
5. Berg EL, Yang J, Melrose J, Nguyen D, Privat S, Rosler E, Kunkel EJ, Ekins S. 2010. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. Journal of Pharmacological and Toxicological Methods 61:3–15. doi: 10.1016/j.vascn.2009.10.001, PMID: 19879948
6. Boyer TG. 2015. Transcriptional kinases: Less is more (or less). Nature Chemical Biology 12:4–5. doi: 10.1038/nchembio.1985
7. Chattopadhyay I, Singh A, Phukan R, Purkayastha J, Kataki A, Mahanta J, Saxena S, Kapur S. 2010. Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India. Mutation Research 696:130–138. doi: 10.1016/j.mrgentox.2010.01.001, PMID: 20083228
8. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, Gray NS, Young RA, George RE. 2014. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159:1126–1139. doi: 10.1016/j.cell.2014.10.024, PMID: 25416950
9. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, et al. 2014. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26:909–922. doi: 10.1016/j.ccell.2014.10.019, PMID: 25490451
10. Czodrowski P, Mallinger A, Wienke D, Esdar C, Pöschke O, Busch M, Rohdich F, Eccles SA, Ortiz-Ruiz MJ, Schneider R, Raynaud FI, Clarke PA, Musil D, Schwarz D, Dale T, Urbahns K, Blagg J, Schiemann K. 2016. Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening. Journal of Medicinal Chemistry 59:9337–9349. doi: 10.1021/acs.jmedchem.6b00597, PMID: 27490956
11. Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, Ewan K, Fraser E, TePoele R, Court W, Box G, Valenti M, de Haven Brandon A, et al. 2015. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology 11:973–980. doi: 10.1038/nchembio.1952, PMID: 26502155
12. Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Löwik CW. 2002. Exposure of KS483 cells to estrogen enhances Osteogenesis and inhibits adipogenesis. Journal of Bone and Mineral Research 17:394–405. doi: 10.1359/jbmr.2002.17.3.394, PMID: 11878304
13. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, Blagg J, Aherne W, Dale T. 2010. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Research 70:5963–5973. doi: 10.1158/0008-5472.CAN-10-1028, PMID: 20610623
14. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, et al. 2008. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547–551. doi: 10.1038/nature07179, PMID: 18794900
15. Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S. 2010. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International Journal of Cancer 126:2863–2873. doi: 10.1002/ijc.24908, PMID: 1 9790197
16. Frye SV. 2010. The art of the chemical probe. Nature Chemical Biology 6:159–161. doi: 10.1038/nchembio.296, PMID: 20154659
17. Fryer CJ, White JB, Jones KA. 2004. Mastermind recruits CycC:CDK8 to phosphorylate the notch ICD and coordinate activation with turnover. Molecular Cell 16:509–520. doi: 10.1016/j.molcel.2004.10.014, PMID: 15546612
18. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. 2013. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell 153:1327–1339. doi: 10.1016/j.cell.2013.04.048, PMID: 23746844
19. Ganuza M, Sáiz-Ladera C, Cañamero M, Gómez G, Schneider R, Blasco MA, Pisano D, Paramio JM, Santamaría D, Barbacid M. 2012. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. The EMBO Journal 31:2498–2510. doi: 10.1038/emboj.2012.94, PMID: 22505032
20. Gu W, Wang C, Li W, Hsu FN, Tian L, Zhou J, Yuan C, Xie XJ, Jiang T, Addya S, Tai Y, Kong B, Ji JY. 2013. Tumor-suppressive effects of CDK8 in endometrial cancer cells. Cell Cycle 12:987–999. doi: 10.4161/cc.24003, PMID: 23454913
21. Hirata A, Utikal J, Yamashita S, Aoki H, Watanabe A, Yamamoto T, Okano H, Bardeesy N, Kunisada T, Ushijima T, Hara A, Jaenisch R, Hochedlinger K, Yamada Y. 2013. Dose-dependent roles for canonical wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Development 140:66–75. doi: 10.1242/dev.084103, PMID: 23222438
22. Jardé T, Evans RJ, McQuillan KL, Parry L, Feng GJ, Alvares B, Clarke AR, Dale TC. 2013. In vivo and in vitro models for the therapeutic targeting of wnt signaling using a Tet-OΔN89β-catenin system. Oncogene 32:883–893. doi: 10.1038/onc.2012.103, PMID: 22469981
23. Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH. 2016. Development of a potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. ACS Medicinal Chemistry Letters 7:223–228. doi: 10.1021/acsmedchemlett.5b00278, PMID: 26985305
24. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, et al. 2014. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511:616–620. doi: 10.1038/nature13393, PMID: 25043025
25. Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, Bury L, Meyer CA, Ke N, Mulry KA, Kluk MJ, et al. 2014. Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology 16:1080–1091. doi: 10.1038/ncb3046, PMID: 25344755
26. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153:320–334. doi: 10.1016/j.cell.2013.03.036, PMID: 23582323
27. Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, Box G, Ortiz-Ruiz MJ, Valenti M, De Haven Brandon A, TePoele R, Leuthner B, Workman P, et al. 2015. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. Journal of Medicinal Chemistry 58:1717–1735. doi: 10.1021/jm501436m, PMID: 25680029
28. Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, Ortiz-Ruiz MJ, Schneider R, Thai C, Valenti M, de Haven Brandon A, Burke R, Workman P, et al. 2016a. Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. Journal of Medicinal Chemistry 59:1078–1101. doi: 10.1021/acs.jmedchem.5b01685, PMID: 26796641
29. Mallinger A, Schiemann K, Rink C, Sejberg J, Honey MA, Czodrowski P, Stubbs M, Poeschke O, Busch M, Schneider R, Schwarz D, Musil D, Burke R, Urbahns K, Workman P, Wienke D, Clarke PA, Raynaud FI, Eccles SA, Esdar C, et al. 2016b. 2,8-Disubstituted-1,6-naphthyridines and 4,6-disubstituted-isoquinolines with potent, selective affinity for CDK8/19. ACS Medicinal Chemistry Letters 7:573–578. doi: 10.1021/acsmedchemlett.6b00022, PMID: 27326329
30. McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. 2015. Cdk8 deletion in the apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. The Journal of Pathology 237:508–519. doi: 10.1002/path.4596, PMID: 26235356
31. Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, Plavec AM, Nguyen D, Johnston ED, Yang J, Polokoff MA, Plavec I, Berg EL, O’Mahony A. 2013. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One 8:e58966. doi: 10.1371/journal.pone.0058966, PMID: 23505568
32. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP. 2006. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6:159–175. doi: 10.1186/1471-2407-6-159, PMID: 16780590
33. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Näär AM, Dyson NJ. 2008. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455:552–556. doi: 10.1038/nature07310, PMID: 18794899
34. Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, Si C, Ebmeier CC, Bronson RT, Krivtsov AV, Myers AG, et al. 2015. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526:273–276. doi: 10.1038/nature14904, PMID: 26416749
35. Poss ZC, Ebmeier CC, Odell AT, Tangpeerachaikul A, Lee T, Pelish HE, Shair MD, Dowell RD, Old WM, Taatjes DJ. 2016. Identification of mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics. Cell Reports 15:436–450. doi: 10.1016/j.celrep.2016.03.030, PMID: 27050516
36. Poss ZC, Ebmeier CC, Taatjes DJ. 2013. The mediator complex and transcription regulation. Critical Reviews in Biochemistry and Molecular Biology 48:575–608. doi: 10.3109/10409238.2013.840259, PMID: 24088064
37. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Müller M, Decker T, Sexl V. 2013. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Reports 4:437–444. doi: 10.1016/j.celrep.2013.07.012, PMID: 23933255
38. Rzymski T, Mikula M, Wiklik K, Brzózka K. 2015. CDK8 kinase–An emerging target in targeted cancer therapy. Biochimica et Biophysica Acta 1854:1617–1629. doi: 10.1016/j.bbapap.2015.05.011, PMID: 26006748
39. Sato S, Tomomori-Sato C, Parmely TJ, Florens L, Zybailov B, Swanson SK, Banks CA, Jin J, Cai Y, Washburn MP, Conaway JW, Conaway RC. 2004. A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology. Molecular Cell 14:685–691. doi: 10.1016/j.molcel.2004.05.006, PMID: 15175163
40. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J. 2016. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. Bioorganic & Medicinal Chemistry Letters 26:1443–1451. doi: 10.1016/j.bmcl.2016.01.062, PMID: 26852363
41. Schroder K, Spille M, Pilz A, Lattin J, Bode KA, Irvine KM, Burrows AD, Ravasi T, Weighardt H, Stacey KJ, Decker T, Hume DA, Dalpke AH, Sweet MJ. 2007. Differential effects of CpG DNA on IFN-beta induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in Macrophages. The Journal of Immunology 179:3495–3503. doi: 10.4049/jimmunol.179.6.3495
42. Seo JO, Han SI, Lim SC. 2010. Role of CDK8 and beta-catenin in colorectal adenocarcinoma. Oncology Reports 24:285–291. doi: 10.3892/or_00000858, PMID: 20514474
43. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O’Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA. 2009. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323:1747–1750. doi: 10.1126/science.1163040, PMID: 19251594
44. Taatjes DJ, Näär AM, Andel F, Nogales E, Tjian R. 2002. Structure, function, and activator-induced conformations of the CRSP coactivator. Science 295:1058–1062. doi: 10.1126/science.1065249, PMID: 11834 832
45. Tsutsui T, Umemura H, Tanaka A, Mizuki F, Hirose Y, Ohkuma Y. 2008. Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-dependent transcriptional regulation. Genes to Cells: Devoted to Molecular & Cellular Mechanisms 13:817–826. doi: 10.1111/j.1365-2443.2008.01208.x, PMID: 18651850
46. Wang F, Scoville D, He XC, Mahe MM, Box A, Perry JM, Smith NR, Lei NY, Davies PS, Fuller MK, Haug JS, McClain M, Gracz AD, Ding S, Stelzner M, Dunn JC, Magness ST, Wong MH, Martin MG, Helmrath M, et al. 2013. Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay. Gastroenterology 145:383–395. doi: 10.1053/j.gastro.2013.04.050, PMID: 23644405
47. Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. 2015. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163:174–186. doi: 10.1016/j.cell.2015.08.063, PMID: 26406377
48. Westerling T, Kuuluvainen E, Mäkelä TP. 2007. Cdk8 is essential for preimplantation mouse development. Molecular and Cellular Biology 27:6177–6182. doi: 10.1128/MCB.01302-06, PMID: 17620419
49. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153:307–319. doi: 10.1016/j.cell.2013.03.035, PMID: 23582322
50. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA, Committee of the National Cancer Research Institute. 2010. Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer 102:1555–1577. doi: 10.1038/sj.bjc.6605642, PMID: 20502460
51. Yin JW, Wang G. 2014. The mediator complex: a master coordinator of transcription and cell lineage development. Development 141:977–987. doi: 10.1242/dev.098392, PMID: 24550107
52. Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS. 2016. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology 12:876–884. doi: 10.1038/nchembio.2166, PMID: 27571479
53. Zhao J, Ramos R, Demma M. 2013. CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. Oncogene 32:3520–3530. doi: 10.1038/onc.2012.364, PMID: 22945643
54. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, Sun Y, Yang ES, Liu LP, Vaitheesvaran B, Bridges L, Kurland IJ, Strich R, Ni JQ, Wang C, Ericsson J, Pessin JE, Ji JY, Yang F. 2012. Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. The Journal of Clinical Investigation 122:2417–2427. doi: 10.1172/JCI61462, PMID: 22684109